2025
- Award: Excellence in Teaching Award, 2025.
- Award: Pauline Ruyle Moore Scholar Award, for On the Appeal of Drug Patent Challenges, 2025.
-
Article: Infringing Patents, but Not by Choice, ABA Landslide, forthcoming 2025
- A farmer’s herbicide blows onto the neighbors’ fields, forcing them to buy patented resistant seeds lest their crops die. Business as usual, or a threat to the foundations of patent law?
-
Article: What Is Copyrightable in Software?, 94 George Washington Law Review (forthcoming 2025)
- Solving a fifty-year-old software copyright law puzzle, by delving into the world of register variables and list comprehensions.
-
Amicus Brief: Jazz Pharmaceuticals, Inc. v. Kennedy, No. 24-5262 (D.C. Cir. filed Mar. 24, 2025)
- For 12 Narcolepsy Patients, Public Interest Organizations, Medical Professionals, and Professors of Law
-
Amicus Brief: Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 (U.S. filed Mar. 20, 2025)
- For 30 Scholars of Law, Economics, and Medicine
- Book: Stephen Clowney et al., Open Source Property: AUWCL Edition (Charles Duan, 2025)
2024
-
Book Chapter: If Not Patents, Then Trade Secrets? (forthcoming 2025)
- In Research Handbook on Trade Secrecy in Data and Data Infrastructure
- A seemingly self-evident trope of patent policy logic is not as simple as it seems.
-
Article: Certainly Uncertain: An Analysis of the Patent Eligibility Restoration Act of 2023, 13 American University Business Law Review (forthcoming 2025)
- A new patent reform bill, intended to crumble two centuries of jurisprudence, is not as well-reasoned as its proponents claim it to be.
-
Amicus Brief: Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 23-1169 (Fed. Cir. Aug. 22, 2024)
- For 15 Scholars of Law and Medicine
-
Amicus Brief: Carroll Shelby Licensing Inc. v. Halicki, Nos. 23-3731, -4008 (9th Cir. filed Nov. 21, 2023)
- For 20 Professors of Law and Public Knowledge
- Book: The Barons and the Mob: Essays on Centralized Platforms and Decentralized Crowds (Charles Duan & James Grimmelmann, 2024) ssrn
- Online Article: USPTO Seeks Public Input on Patents and the Right to Research, InfoJustice, July 10, 2024
-
Article: Examining Patent Eligibility, 97 St. John’s Law Review 47 (2023) ssrn
- A little-studied 2011 Federal Circuit decision had major ripple effects on patent eligibility and examination practice, in ways that challenge dominant policy narratives about the doctrine.
- Media coverage: ELSIhub
- Award: Best Publication of 2023 on Antitrust and Intellectual Property, Jerry S. Cohen Memorial Fund Writing Award, for Mandatory Infringement, 2024.
- Book Chapter: Toward a Legal Framework for Patient Access to At-Home Health Care Device Data (2024) ssrn
-
Book Chapter: Patent Title Insurance (2024)
- In Handbook of Intellectual Property Rights and Innovation
- Homeowners buy title insurance, in case they turn out not to be the true owner of their houses. Should patent owners also get insurance, in case they aren’t the first to invent their ideas?
-
Article: Content Moderation on End-to-End Encrypted Systems: A Legal Analysis, 8 Georgetown Law Technology Review 1 (2024) ssrn
- With James Grimmelmann
- Computer scientists have come up with cutting-edge technologies for content moderation on end-to-end encrypted platforms. Are those technologies legal?
2023
-
Essay: Securing Patent Law, 11 Belmont Law Review 91 (2023) ssrn
- The conversation on intellectual property and national security needs to focus more on technological competitor nations’ potential use of U.S. patents as an offense strategy.
-
Amicus Brief: Green v. United States Department of Justice, 111 F.4th 81 (D.C. Cir. 2024)
- For Public Knowledge, the Digital Right to Repair Coalition, Software Freedom Conservancy, iFixit, the Open Source Hardware Association, and Scholars of Property and Technology Law
-
Amicus Brief: Jazz Pharmaceuticals v. Becerra, No. 1:23-cv-1819 (D.D.C. Oct. 30, 2024)
- For 22 Narcolepsy Patients, Public Interest Organizations, Medical Professionals, and Professors of Law
-
Article: On the Appeal of Drug Patent Challenges, 72 American University Law Review 1177 (2023) ssrn
- Empirically, inter partes review patent challenges have been accurate and effective at lowering drug prices. But the Federal Circuit’s publication practices hide those facts.
-
Article: Mandatory Infringement, 75 Florida Law Review 219 (2023) ssrn
- Exploring the unexpected effects of intellectual property/regulation overlaps on market power, innovation incentives, and intellectual property theory.
-
Hearing Testimony: Intellectual Property and Strategic Competition with China: Part I, House of Representatives, 117th Cong. (2023)
- Invited witness before the Subcomm. on Courts, Intellectual Property, and the Internet of the H. Comm. on the Judiciary
2022
-
Article: Pharmaceutical Patent Two-Step: The Adverse Advent of Amarin v. Hikma Type Litigation, 12 New York University Journal of Intellectual Property and Entertainment Law 1 (2022)
- With S. Sean Tu
- Buried within a tangled web of patents surrounding a widely used cardiovascular drug are the seeds of a legal strategy that could delay generics for years to come.
-
Book Chapter: A Failure to Interoperate: The Lost Mars Climate Orbiter (2022)
- In “You Are Not Expected to Understand This”: How 26 Lines of Code Changed the World
- A failed NASA mission’s lessons for modern information and Internet technology.
-
Amicus Brief: American Society for Testing & Materials v. Public.Resource.Org, Inc., 82 F.4th 1262 (D.C. Cir. 2022)
- For Former Government Publishing Officials Raymond A. Mosley and Robert C. Tapella
-
Press Article: Prevent a Legal Catch-22 That Could Push Thousands of Generic Drugs Off the Market, Los Angeles Times, Sept. 21, 2022, at A13
- With Michael A. Carrier & S. Sean Tu
-
Amicus Brief: Teva Pharmaceuticals USA v. GlaxoSmithKline LLC, No. 22-37 (U.S. July 11, 2022)
- For 42 Professors of Law, Economics, Business, and Medicine
Last updated: Fri, 23 May 2025 11:53:35 -0400